IL10 and neoplasm: The further study found that the STAT1/STAT3 signaling pathway in tumor cells activated by IL-10 inhibited the PERK signaling pathway and alleviated the ER stress-mediated cell death in tumor cells caused by CAP treatment (Fig. 7).